Mark Mason

Mark Mason, PhD, is a strategic and analytical thinker with over a decade of experience in drug development, focusing on inflammation, immuno-oncology, and early disease detection. Currently serving as Project Lead in Drug Development at Numab Therapeutics AG, they leverage their extensive knowledge to enhance patient outcomes. Previously, Mason held roles such as Director of Research and Development at AVMBioMed, where they built and managed scientific teams and fostered relationships with industry partners. They earned their Doctor of Philosophy in Chemistry/Biochemistry from the University of Pennsylvania, conducting impactful research on protein structures and functions.